[S29] The consideration of the ideal form of PMDA's review reports as drug information —from the perspectives of the regulatory authorities, medical institutions, and industries— | The 145th Annual Meeting of the Pharmaceutical Society of Japan (Fukuoka)

Session Details

Symposium

Fri. Mar 28, 2025 1:15 PM - 2:45 PM JST
Fri. Mar 28, 2025 4:15 AM - 5:45 AM UTC

Room 7 (Fukuoka International Congress Center: 204 [2F])

Organizer: Wakabayashi Susumu (Kyorin University Hospital), Yuji Kashitani (Takeda Pharm.)

1:15 PM - 1:20 PM JST(4:15 AM - 4:20 AM UTC)

1:20 PM - 1:25 PM JST(4:20 AM - 4:25 AM UTC)

○Yasutsugu Nakano^1,2 (1. Japan Pharmaceutical Manufacturers Association, 2. Shionogi & Co., Ltd.)

1:25 PM - 1:40 PM JST(4:25 AM - 4:40 AM UTC)

○Takashi Yasukawa¹ (1. Pharmaceuticals and Medical Devices Agency)

1:40 PM - 1:55 PM JST(4:40 AM - 4:55 AM UTC)

○Susumu Wakabayashi^1,2 (1. Kyorin University Hospital, 2. Tokyo Healthcare University)

1:55 PM - 2:10 PM JST(4:55 AM - 5:10 AM UTC)

○Tadashi Ishihara^1,2 (1. 日本製薬工業協会, 2. Bayer Yakuhin)

2:10 PM - 2:40 PM JST(5:10 AM - 5:40 AM UTC)

2:40 PM - 2:45 PM JST(5:40 AM - 5:45 AM UTC)